Get the Stockscreener App
0.0109
85.99%
-0.0669
Viracta Therapeutics Inc stock is traded at $0.0109, with a volume of 1.44M.
It is down -85.99% in the last 24 hours and down -94.83% over the past month.
See More
Previous Close:
$0.0778
Open:
$0.0116
24h Volume:
1.44M
Relative Volume:
0.60
Market Cap:
$1.40M
Revenue:
-
Net Income/Loss:
$-43.29M
P/E Ratio:
-0.00991
EPS:
-1.1
Net Cash Flow:
$-34.80M
1W Performance:
-92.81%
1M Performance:
-94.83%
6M Performance:
-97.58%
1Y Performance:
-98.05%
1-Day Range:
$0.0102
$0.015
1-Week Range:
$0.0102
$0.105
52-Week Range:
$0.0102
$1.31
Viracta Therapeutics Inc Stock (VIRX) Company Profile
Name
Viracta Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare VIRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIRX
Viracta Therapeutics Inc
|
0.0112 | 1.40M | 0 | -43.29M | -34.80M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.55 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.69 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.72 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-16-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-01-22 | Initiated | RBC Capital Mkts | Outperform |
| May-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Initiated | SVB Leerink | Outperform |
| Mar-25-21 | Initiated | Evercore ISI | Outperform |
Viracta Therapeutics Inc Stock (VIRX) Latest News
Viracta Therapeutics Terminates Employees & Winds Down Operations - Contract Pharma
Fierce Biotech Layoff Tracker 2025: Viracta shuts down; Layoffs hit Frontier - Fierce Biotech
Viracta Therapeutics to cease operations and seek alternatives - MSN
Viracta Therapeutics Announces Wind Down of Operations - GlobeNewswire
Viracta Therapeutics to cease operations and seek alternatives By Investing.com - Investing.com South Africa
Viracta Therapeutics Announces Wind Down Of Operations -February 05, 2025 at 06:39 pm EST - Marketscreener.com
Viracta Therapeutics Announces Wind-Down and Leadership Changes - TipRanks
Oncology Biotech Viracta Collapses: Development Programs Halted as Company Shuts Down - StockTitan
Leerink Partners slashes price target on Viracta Therapeutics Inc [VIRX] – find out why. - The DBT News
Views of Wall Street’s Leading Experts on Viracta Therapeutics Inc - SETE News
VIRX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Analyzing VIRX’s price-to-book ratio for the last quarter - US Post News
VIRX stock plunges to 52-week low, touches $0.08 - Investing.com
Viracta Therapeutics to be delisted from Nasdaq - MSN
Viracta Therapeutics strikes deal to avoid default - MSN
Viracta Therapeutics strikes deal to avoid default By Investing.com - Investing.com South Africa
Viracta Therapeutics (VIRX) Stock Price, News & Analysis - MarketBeat
Viracta Therapeutics faces Nasdaq delisting over audit issue By Investing.com - Investing.com Canada
Viracta Therapeutics faces Nasdaq delisting over audit issue - MSN
BioLineRx announces $10M registered direct offering; shares tumble - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Viracta Therapeutics (NASDAQ:VIRX) Given “Neutral” Rating at Rodman & Renshaw - Defense World
Rodman & Renshaw Downgrades Viracta Therapeutics (VIRX) - MSN
Viracta Therapeutics Explores Strategic Options After NAVAL-1 Closure - Yahoo Finance
Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues - Benzinga
Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED) - Benzinga
ServiceTitan initiated, Viracta downgraded: Wall Street's top analyst calls - Yahoo Finance
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Masimo To Rally More Than 13%? Here Are 5 Top Analyst Forecasts For Friday - Benzinga
Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday - Benzinga
Viracta Therapeutics, Inc. Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - Marketscreener.com
Viracta Therapeutics Ends Naval-1 Clinical Trial and Is Exploring Strategic Alternatives - MarketWatch
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives - GlobeNewswire
Viracta Therapeutics (VIRX) Halts Phase 2 NAVAL-1 Trial, Explores Strategic Alternatives Amid Resource Conservation - StockTitan
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World
Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com
Viracta Therapeutics Inc Stock (VIRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viracta Therapeutics Inc Stock (VIRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pomerantz Roger | Director |
Nov 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
126,478 |
| ROYSTON IVOR | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
814,522 |
| Pomerantz Roger | Director |
Aug 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
117,444 |
| Pomerantz Roger | Director |
May 25 '24 |
Option Exercise |
0.00 |
9,035 |
0 |
108,410 |
| ROYSTON IVOR | Director |
May 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
789,303 |
| ROYSTON IVOR | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
25,219 |
0 |
764,084 |
| Pomerantz Roger | Director |
Feb 25 '24 |
Option Exercise |
0.00 |
9,034 |
0 |
99,375 |
| Chevallard Daniel R. | CFO and COO |
Feb 25 '24 |
Option Exercise |
0.00 |
6,889 |
0 |
105,711 |
| Chevallard Daniel R. | CFO and COO |
Feb 27 '24 |
Sale |
0.73 |
3,405 |
2,493 |
102,306 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):